Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis

  • Ebos J
  • Kerbel R
  • 6


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease progression in some patients, leading to progression-free survival (PFS) and overall survival benefits compared with controls. However, the results are more modest than predicted by most preclinical testing and benefits in PFS are frequently not accompanied by overall survival improvements. Questions have emerged about the basis of drug resistance and the limitations of predictive preclinical models, and also about whether the nature of disease progression following antiangiogenic therapy is different to classic cytotoxic therapies - in particular whether therapy may lead to more invasive or metastatic behavior. In addition, because of recent clinical trial failures of antiangiogenic therapy in patients with early-stage disease, and the fact that there are hundreds of trials underway in perioperative neoadjuvant and adjuvant settings, there is now greater awareness about the lack of appropriate preclinical testing that preceded these studies. Improved preclinical assessment of all stages of metastatic disease should be a priority for future antiangiogenic drug discovery and development. (copyright) 2011 Macmillan Publishers Limited. All rights reserved.

Author-supplied keywords

  • NCT00004252
  • NCT00021281
  • NCT00083889
  • NCT00428597
  • UFT
  • adrenal cancer
  • advanced cancer
  • alpha2 interferon
  • angiogenesis inhibitor
  • anthracycline
  • antiangiogenic therapy
  • antineoplastic agent
  • bevacizumab
  • bladder cancer
  • breast cancer
  • cancer adjuvant therapy
  • cancer combination chemotherapy
  • cancer hormone therapy
  • cancer prevention
  • cancer radiotherapy
  • cancer resistance
  • cancer staging
  • capecitabine
  • carboplatin
  • central nervous system tumor
  • cetuximab
  • cisplatin
  • clinical effectiveness
  • colorectal cancer
  • cpt 11
  • cyclophosphamide
  • distant metastasis
  • docetaxel
  • dose response
  • drug effect
  • drug efficacy
  • drug fatality
  • drug potency
  • drug safety
  • erlotinib
  • esophagus cancer
  • fluorouracil
  • folinic acid
  • gastrointestinal stromal tumor
  • gastrointestinal tumor
  • gemcitabine
  • glioblastoma
  • head and neck cancer
  • head and neck carcinoma
  • human
  • irinotecan
  • kidney cancer
  • kidney carcinoma
  • liver cell carcinoma
  • liver metastasis
  • low drug dose
  • lung non small cell cancer
  • melanoma
  • metastasis
  • micrometastasis
  • multiple cycle treatment
  • nonhuman
  • ovary cancer
  • overall survival
  • oxaliplatin
  • paclitaxel
  • pancreas cancer
  • pancreas islet cell tumor
  • pazopanib
  • primary tumor
  • priority journal
  • progression free survival
  • prostate cancer
  • protein tyrosine kinase inhibitor
  • ptk 787
  • rebound
  • rectum cancer
  • review
  • semaxanib
  • signal transduction
  • soft tissue sarcoma
  • sorafenib
  • squamous cell carcinoma
  • stomach cancer
  • sunitinib
  • taxane derivative
  • treatment duration
  • tumor escape
  • tumor invasion
  • tumor localization
  • urogenital tract cancer
  • uterine cervix cancer
  • uvea melanoma
  • vandetanib
  • vasculotropin inhibitor
  • vatalanib
  • vinblastine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • J M L Ebos

  • R S Kerbel

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free